ITOS ITEOS THERAPEUTICS INC revenue, earnings and financials
For the quarter ended June 30, 2025, ITEOS THERAPEUTICS INC reported revenue of $0 (down 100.0% from a year earlier), net income of −$78.7M and diluted EPS of −$1.81; for the fiscal year ended December 2024 revenue was $35.0M, up 177.9% on the year before.
ITOS annual revenue and earnings
- Fiscal year ended Dec 2024: revenue $35.0M, gross profit n/a, operating income −$160M, net income −$134M (margin -384.0%), EPS −$3.32
- Fiscal year ended Dec 2023: revenue $12.6M, gross profit n/a, operating income −$151M, net income −$113M (margin -894.3%), EPS −$3.15
- Fiscal year ended Dec 2022: revenue $268M, gross profit n/a, operating income $126M, net income $96.7M (margin 36.1%), EPS $2.56
- Fiscal year ended Dec 2021: revenue $345M, gross profit n/a, operating income $245M, net income $215M (margin 62.2%), EPS $5.68
ITOS quarterly revenue and earnings
- Quarter ended Jun 30, 2025: revenue $0 (down 100.0% year over year), net income −$78.7M, EPS −$1.81
- Quarter ended Mar 31, 2025: revenue n/a, net income −$34.6M, EPS −$0.80
- Quarter ended Dec 31, 2024 (from the annual report): revenue $0, net income −$43.7M, EPS −$1.02
- Quarter ended Sep 30, 2024: revenue $0, net income −$45.4M, EPS −$1.05
- Quarter ended Jun 30, 2024: revenue $35.0M, net income −$7.13M, EPS −$0.18
- Quarter ended Mar 31, 2024: revenue $0 (down 100.0% year over year), net income −$38.2M, EPS −$1.07
- Quarter ended Dec 31, 2023 (from the annual report): revenue $0 (down 100.0% year over year), net income −$30.6M, EPS −$0.85
- Quarter ended Sep 30, 2023: revenue $0 (down 100.0% year over year), net income −$32.2M, EPS −$0.90
- Quarter ended Jun 30, 2023: revenue $0 (down 100.0% year over year), net income −$34.3M, EPS −$0.96
- Quarter ended Mar 31, 2023: revenue $12.6M (down 91.7% year over year), net income −$15.6M, EPS −$0.44
- Quarter ended Dec 31, 2022 (from the annual report): revenue $53.9M, net income $20.5M, EPS $0.56
- Quarter ended Sep 30, 2022: revenue $19.5M (down 81.3% year over year), net income $991K, EPS $0.03
- Quarter ended Jun 30, 2022: revenue $41.7M, net income $5.63M, EPS $0.15
- Quarter ended Mar 31, 2022: revenue $153M, net income $69.6M, EPS $1.82
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income $185M, EPS $4.96
- Quarter ended Sep 30, 2021: revenue $104M, net income $69.6M, EPS $1.86
- Quarter ended Jun 30, 2021: revenue n/a, net income −$26.5M, EPS −$0.75
- Quarter ended Mar 31, 2021: revenue n/a, net income −$13.5M, EPS −$0.39
ITOS cash flow, buybacks and dividends
- Fiscal year ended Dec 2024: operating cash flow −$98.2M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$104M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$111M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow $513M, share buybacks n/a
ITOS balance sheet
- Jun 30, 2025: cash $208M, total assets $623M, total liabilities $129M, shareholders' equity $494M
- Mar 31, 2025: cash $157M, total assets $659M, total liabilities $95.4M, shareholders' equity $563M
- Dec 31, 2024: cash $142M, total assets $687M, total liabilities $96.7M, shareholders' equity $590M
- Sep 30, 2024: cash $124M, total assets $723M, total liabilities $91.4M, shareholders' equity $632M
- Jun 30, 2024: cash $251M, total assets $752M, total liabilities $88.0M, shareholders' equity $664M
- Mar 31, 2024: cash $147M, total assets $630M, total liabilities $88.6M, shareholders' equity $541M
- Dec 31, 2023: cash $251M, total assets $668M, total liabilities $92.4M, shareholders' equity $575M
- Sep 30, 2023: cash $204M, total assets $678M, total liabilities $79.4M, shareholders' equity $598M
What is ITOS's revenue?
ITEOS THERAPEUTICS INC reported $35.0M of revenue for the fiscal year ended December 2024.
Is ITOS profitable?
No. ITEOS THERAPEUTICS INC lost $202M over the last four quarters.
What is ITOS's EPS?
Diluted earnings per share over the last four quarters were −$4.68; −$1.81 in the latest quarter.